Image

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Recruiting
40 years and older
All
Phase 2

Powered by AI

Overview

The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease.

Description

[68Ga]CBP8, is a PET imaging probe which selectively binds collagen type I. Collagen deposition is a pivotal event in the development of pulmonary fibrosis. [68Ga]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles. [68Ga]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis and response to treatment. In addition, [68Ga]CBP8 can detect increased collagen in the lungs of patients with idiopathic pulmonary fibrosis.

The goals of this study are:

  1. To determine whether collagen deposition as assessed by [68Ga]CBP8-PET MRI can detect increased collagen deposition in early interstitial lung disease and
  2. if the degree of [68Ga]CBP8 uptake predicts subsequent disease progression.

Eligibility

Inclusion Criteria:

Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8)

  • Age greater than 40 years
  • Have the ability to give written informed consent
  • First degree relative of a family member with pulmonary fibrosis
  • No known history of interstitial lung disease
  • No tobacco use within the prior 6 months.
        Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease
        (ILD) (n=22)
          -  Age greater than 40 years
          -  Have the ability to give written informed consent
          -  ILAs or early ILD (defined by presence of reticular markings and / or traction
             bronchiectasis but absence of a definite UIP pattern)
          -  No tobacco use within the prior 6 months.
        Exclusion criteria:
          -  Electrical implants such as cardiac pacemaker or perfusion pump
          -  Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial
             hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere
             on the body, tattoos near the eye, or steel implants ferromagnetic objects such as
             jewelry or metal clips in clothing
          -  Historical eGFR of less than 30 mL/min/1.73 m2
          -  Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is
             required for females having child-bearing potential before the subject can
             participate)
          -  Claustrophobic reactions
          -  Research-related radiation exposure exceeds current Radiology Department guidelines
             (i.e. 50 mSv in the prior 12 months)
          -  Unable to lie comfortably on a bed inside the MR-PET
          -  BMI > 33 (limit of the PET-MRI table)
          -  Determined by the investigator(s) to be clinically unsuitable for the study (e.g.
             based on screening visit and/or during study procedures)
          -  Pneumonia or other acute respiratory illness within 6 weeks of study entry
          -  Parenchymal lung disease except for ILD/ILAs or emphysema
          -  Acute exacerbation of ILD within the prior 6 months
          -  VATS within the prior 6 months
          -  Prior radiation therapy to the thorax
          -  Known allergy to gadolinium.

Study details
    Interstitial Lung Disease

NCT05417776

Massachusetts General Hospital

29 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.